The use of remdesivir outside of clinical trials during the COVID-19 pandemic

With a scientific background from filoviruses, paramyxoviruses, SARS-CoV, and MERS-CoV, remdesivir entered into the COVID-19 battle to become one of the favorable therapeutic candidates with potential antiviral activity in the treatment of this disease. Globally, remdesivir was accessed and investig...

Descripción completa

Detalles Bibliográficos
Autores principales: Halimi, Vesa, Daci, Armond, Ridova, Nevenka, Panovska-Stavridis, Irina, Stevanovic, Milena, Filipce, Venko, Dimovski, Aleksandar, Grozdanova, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7503054/
https://www.ncbi.nlm.nih.gov/pubmed/32968487
http://dx.doi.org/10.1186/s40545-020-00258-8
Descripción
Sumario:With a scientific background from filoviruses, paramyxoviruses, SARS-CoV, and MERS-CoV, remdesivir entered into the COVID-19 battle to become one of the favorable therapeutic candidates with potential antiviral activity in the treatment of this disease. Globally, remdesivir was accessed and investigated through clinical research (clinical trials) and clinical practice (compassionate use, expanded access, early access scheme, and emergency use). Currently, remdesivir approval status differs between states. This paper aims to review and analyze regulatory approaches for accessing and investigating remdesivir, by communicating regulatory variability between countries in terms of terminology, modalities, and protocols.

Ejemplares similares